NEW YORK, Aug. 13, 2019 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that an article highlighting the synaptic deficiency hypothesis was published online in Trends in Pharmacological Sciences. This

OMAHA, Neb., Aug. 13, 2019 /PRNewswire/ -- Social Isolation is becoming an increasingly common issue, with

VANCOUVER, Aug. 13, 2019 /PRNewswire/ - Harvest One Inc. ("Harvest One" or the "Company") (TSXV: HVT; OTCQX: HRVOF), through its wholly-owned subsidiary Satipharm Ltd. ("Satipharm"), today announced positive results of a Phase 2 clinical trial of its CBD GelPell® capsules in the management of Treatment Resistant Epilepsy (TRE) h

LOS ANGELES, Aug. 13, 2019 /PRNewswire/ -- Advocates, supporters, community leaders, celebrities and healthcare providers join PCOS Chall

ROCKVILLE, Md., Aug. 13, 2019 /PRNewswire/ -- Secure Exchange Solutions (SES), a leading provider of interoperable, cloud-based clinical data exchange technology, announced a

NEW YORK, Aug. 13, 2019 /PRNewswire/ -- Happify Health, a leader in mental health technology and the emerging field of digital therapeutics, announced today the appointment of Murray Zucker, M.D. as Medical Director. Dr. Zucker, a seasoned psychiatrist, will oversee clinical development and enhancements to Happify Health's digital inte

SAN DIEGO, Aug. 13, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable inform

SAN FRANCISCO, Aug. 13, 2019 /PRNewswire/ -- Datavant announced today its selection by the People-Centered Research Foundation (PCRF) to de-identify and link patient data across PCORnet, the National Patient-Centered Clinical Research Network. PCRF is the central office for PCORnet, which has been developed with funding from the Patient-Centered Outcomes Research In

WHIPPANY, N.J., Aug. 13, 2019 /PRNewswire/ -- A head-to-head study directly comparing the pharmacokinetic (PK) profiles of two extended half-life (EHL) recombinant factor VIII (FVIII) therapies demonstrated improved PK characteristics for Jivi® (antihemophilic factor [recombinant] PEGylated-aucl) compared to Eloctate®

NEW YORK and BASEL, Switzerland, Aug. 13, 2019 /PRNewswire/ — Immunovant, a biopharmaceutical company focused on developing innovative therapies for patients living with debilitating autoimmune diseases, today announced the appointment of Robert K. Zeldin, M.D., as Chief Medical Officer and W. Bradford